NSE: APLLTD | BSE: 533573

Mid-range Performer

Download real time

827.35 21.45 (2.66%)

36.55% Fall from 52W High

122.8K NSE+BSE Volume

NSE 13 Mar, 2025 3:31 PM (IST)

16,262.6

Market Cap

High in industry

0.5

Beta 1Year

Very Low volatility

Alembic Pharmaceuticals Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for APLLTD, BSE:533573 Alembic Pharmaceuticals Ltd.

Search Inside the pdf :

Alembic Pharmaceuticals Ltd.

12 Feb 2025

827.35

2.66%

Alembic Pharma (BUY): Earnings recovery on normalised Azithromycin base

Buy: Alembic Pharmaceuticals Ltd.

Target

BOB Capital Markets Ltd.

US and ROW sales grew above our estimates of 5% and 13% respectively, reporting growth of 10% each

Alembic Pharmaceuticals Ltd. is trading below all available SMAs

Alembic Pharmaceuticals Ltd.

06 Feb 2025

827.35

2.66%

Challenges in API business weigh on the performance

Hold: Alembic Pharmaceuticals Ltd.

Target

KRChoksey

Alembic Pharma’s revenue missed our estimates (-2.2%) due to weak growth in domestic and API business. EBITDA fell short of our estimates due to a miss in revenue and higher operating expenses. Adj. PAT missed our estimates due to higher-than-expected tax expenses and lower-than-expected other income.

Alembic Pharmaceutic.. has an average target of 959.00 from 4 brokers.

Alembic Pharmaceuticals Ltd.

04 Feb 2025

827.35

2.66%

In pursuit of a turnaround

Hold: Alembic Pharmaceuticals Ltd.

Recommendation Target

ICICI Securities Limited

Alembic Pharma’s (Alembic) Q3FY25 result was dragged by tepid performance in India and API biz. India biz growth has been weaker (5.8% in 9MFY25) for the last couple of quarters due to pressure in acute segment even though animal health biz has been growing <20%.

Alembic Pharmaceuticals Ltd. has lost -22.10% in the last 3 Months

Alembic Pharmaceuticals Ltd.

03 Feb 2025

827.35

2.66%

Muted India business and lower operating leverage drag earnings

Neutral: Alembic Pharmaceuticals Ltd.

Target

Motilal Oswal

Alembic Pharma (ALPM) delivered operationally in-line 3QFY25 performance. Higher interest outgo and tax led to lower-than-expected earnings for the quarter.

Alembic Pharmaceuticals Ltd. has lost -22.10% in the last 3 Months

Alembic Pharmaceuticals Ltd.

08 Nov 2024

827.35

2.66%

New launches in US and market share gains in Ex-USA will drive growth

Hold: Alembic Pharmaceuticals Ltd.

Target

KRChoksey

Alembic Pharma’s revenue missed our estimate (-4.8%) due to decline in API segment and moderate growth in India and US. However, EBITDA was in-line and Adj. PAT was largely in-line (+2.5%) with our estimate.

Alembic Pharmaceuticals Ltd. is trading below all available SMAs

Alembic Pharmaceuticals Ltd.

07 Nov 2024

827.35

2.66%

API/India trim earnings growth

Neutral: Alembic Pharmaceuticals Ltd.

Target

Motilal Oswal

Alembic Pharma’s (ALPM) 2QFY25 results came in below our estimates due to the deterioration in API business and higher operational costs.

Number of FII/FPI investors decreased from 219 to 213 in Dec 2024 qtr

Alembic Pharmaceuticals Ltd.

07 Nov 2024

827.35

2.66%

Alembic Pharma (BUY): The worst is over; H2FY25 to be better than H1FY25

Buy: Alembic Pharmaceuticals Ltd.

Recommendation Target

BOB Capital Markets Ltd.

Q2FY25 results were below our estimates on all fronts; however, ALPM expects H2 to be better than H1FY25 driven by healthy product mix

Alembic Pharmaceuticals Ltd. has lost -22.10% in the last 3 Months

Alembic Pharmaceuticals Ltd.

13 Aug 2024, 12:00AM

827.35

2.66%

Strong operational performance led by better pricing

Hold: Alembic Pharmaceuticals Ltd.

Target

KRChoksey

Alembic Pharma’s revenue missed our estimate due to lower-than-expected revenue in the Ex-USA segment and lower-than-expected revenue in the API segment. We believe the Company will aim to maintain a growth trajectory in the US with new product launches while continuing to outperform the Indian Pharmaceutical Market in the long term.

Alembic Pharmaceuticals Ltd. is trading below all available SMAs

Alembic Pharmaceuticals Ltd.

14 May 2024, 12:00AM

827.35

2.66%

Lack of visibility on US growth outlook

Hold: Alembic Pharmaceuticals Ltd.

Target

KRChoksey

Alembic Pharma’s revenue missed our estimate slightly due to weak growth in India, Ex-US (other than the US market), and API segments. However, EBITDA beat our estimates due to cost optimization measures and better utilization.